|Event Title||First Global Alliance for Research on Avian Diseases (GARAD) Conference|
|Event Date & Time||On Tue, 30 Jun 2015 at 09:25:00 - 09:45:00|
|Venue||Edmond J. Safra Lecture Theatre|
|Abstract Title||Recombinant Vaccines against Avian Viral Diseases: Current Status and Future Prospects|
|Authors||Abdul R Omar and Aini Ideris|
|Affiliations||Institute of Bioscience, Faculty of Veterinary Medicine, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia|
Currently, the poultry industry is threatened by more virulent viruses of endemic diseases or by exotic and emerging diseases that can cause major economic losses to this sector. The emergence and re-emergence of avian influenza virus (AIV) in particularly highly pathogenic avian influenza (HPAI) H5N1, the presence of endemic low pathogenic avian influenza (LPAI) H9N2 in poultry flock and recently the detection of novel H7H9 and H10N8 posed significant threats to the poultry industry and public health sector. Catastrophic diseases such as HPAI H5N1 is not easy to overlook, the real challenge is to confront H9N2, H7N9 and other LPAI which act in concert with other factors such as management, environment, nutrition and concurrent infections which form continuous threat to the entire poultry production system. Furthermore, the repeated outbreaks of diseases caused by variant strains of infectious bronchitis virus (IBV), velogenic Newcastle disease viruses (NDV) and more virulent viruses of infectious bursal disease virus (IBDV) and Marek’s disease virus (MDV) in well managed poultry flocks have prompted the need to evaluate the underlying factors contributing to the failure of vaccination to provide complete protection against clinical infections and transmission of disease. Undoubtedly, vaccines and vaccination equipment have improved over the years. However, despite these advancements, conventional live and killed vaccines are used extensively in health and disease management of poultry. Most of the advances in the development of the so called recombinant vaccines against poultry diseases are based on the development of recombinant protein/peptide vaccines, recombinant vector vaccines using selected virus or bacteria as carriers and DNA plasmids as genetic/DNA vaccines. However, very few recombinant vaccines are available commercially. The majority of these newer vaccines are live recombinant viral vectors based on fowlpox virus and herpesvirus designed to deliver specific gene(s) to stimulate the host’ immune system. Recently, a few new recombinant viral vector vaccines based on avian adenovirus and reverse genetic NDV and AIV are making their way in several countries. This presentation summarized some key points in determining whether a recombinant viral vaccine is simply a good laboratory idea or a vaccine with clear advantages over existing vaccine.